Zobrazeno 1 - 10
of 468
pro vyhledávání: '"Matthew D. Hellmann"'
Autor:
Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, Chad M. Vanderbilt, Pooja Gogia, Antoine Desilets, Meriem Messaoudene, Daniel Kelly, Marc Ladanyi, Matthew D. Hellmann, Laurence Zitvogel, Charles M. Rudin, Bertrand Routy, Lisa Derosa, Adam J. Schoenfeld
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of antibiotics on clinical o
Externí odkaz:
https://doaj.org/article/6b78137517bb4690816d94fa12584591
Autor:
Kevin Litchfield, James L. Reading, Emilia L. Lim, Hang Xu, Po Liu, Maise Al-Bakir, Yien Ning Sophia Wong, Andrew Rowan, Samuel A. Funt, Taha Merghoub, David Perkins, Martin Lauss, Inge Marie Svane, Göran Jönsson, Javier Herrero, James Larkin, Sergio A. Quezada, Matthew D. Hellmann, Samra Turajlic, Charles Swanton
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
The transcripts generated by frameshifts and indels in cancer are frequently degraded by nonsense mediated decay. Here, the authors show that some of these transcripts can escape this degradation mechanism and their prevalence correlates with tumour
Externí odkaz:
https://doaj.org/article/5361db97aec7487d9e4b4732b41ccecf
Autor:
Narek Shaverdian, Maria Thor, Annemarie F. Shepherd, Michael D. Offin, Andrew Jackson, Abraham J. Wu, Daphna Y. Gelblum, Ellen D. Yorke, Charles B. Simone II, Jamie E. Chaft, Matthew D. Hellmann, Daniel R. Gomez, Andreas Rimner, Joseph O. Deasy
Publikováno v:
Cancer Medicine, Vol 9, Iss 13, Pp 4622-4631 (2020)
Abstract Introduction Durvalumab after concurrent chemoradiation (cCRT) is now standard of care for unresected stage III non–small cell lung cancer (NSCLC). However, there is limited data on radiation pneumonitis (RP) with this regimen. Therefore,
Externí odkaz:
https://doaj.org/article/50d800fc23384e0fb29bee7b87b27705
Autor:
Xuemei Ji, Semanti Mukherjee, Maria Teresa Landi, Yohan Bosse, Philippe Joubert, Dakai Zhu, Ivan Gorlov, Xiangjun Xiao, Younghun Han, Olga Gorlova, Rayjean J. Hung, Yonathan Brhane, Robert Carreras-Torres, David C. Christiani, Neil Caporaso, Mattias Johansson, Geoffrey Liu, Stig E. Bojesen, Loic Le Marchand, Demetrios Albanes, Heike Bickeböller, Melinda C. Aldrich, William S. Bush, Adonina Tardon, Gad Rennert, Chu Chen, Jinyoung Byun, Konstantin H. Dragnev, John K. Field, Lambertus FA. Kiemeney, Philip Lazarus, Shan Zienolddiny, Stephen Lam, Matthew B. Schabath, Angeline S. Andrew, Pier A. Bertazzi, Angela C. Pesatori, Nancy Diao, Li Su, Lei Song, Ruyang Zhang, Natasha Leighl, Jakob S. Johansen, Anders Mellemgaard, Walid Saliba, Christopher Haiman, Lynne Wilkens, Ana Fernandez-Somoano, Guillermo Fernandez-Tardon, Erik H. F. M. van der Heijden, Jin Hee Kim, Michael P. A. Davies, Michael W. Marcus, Hans Brunnström, Jonas Manjer, Olle Melander, David C. Muller, Kim Overvad, Antonia Trichopoulou, Rosario Tumino, Gary E. Goodman, Angela Cox, Fiona Taylor, Penella Woll, Erich Wichmann, Thomas Muley, Angela Risch, Albert Rosenberger, Kjell Grankvist, Mikael Johansson, Frances Shepherd, Ming-Sound Tsao, Susanne M. Arnold, Eric B. Haura, Ciprian Bolca, Ivana Holcatova, Vladimir Janout, Milica Kontic, Jolanta Lissowska, Anush Mukeria, Simona Ognjanovic, Tadeusz M. Orlowski, Ghislaine Scelo, Beata Swiatkowska, David Zaridze, Per Bakke, Vidar Skaug, Lesley M. Butler, Kenneth Offit, Preethi Srinivasan, Chaitanya Bandlamudi, Matthew D. Hellmann, David B. Solit, Mark E. Robson, Charles M. Rudin, Zsofia K. Stadler, Barry S. Taylor, Michael F. Berger, Richard Houlston, John McLaughlin, Victoria Stevens, David C. Nickle, Ma’en Obeidat, Wim Timens, María Soler Artigas, Sanjay Shete, Hermann Brenner, Stephen Chanock, Paul Brennan, James D. McKay, Christopher I. Amos
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
In lung cancer, relatively few germline mutations are known to impact risk. Here the authors looked at rare variants in 39,146 individuals and find novel germline mutations associated with risk, as well as implicating ATM and a new candidate gene for
Externí odkaz:
https://doaj.org/article/98db56edb20d4123b824401859c438ab
Autor:
Narek Shaverdian, MD, Michael Offin, MD, Annemarie F. Shepherd, MD, Matthew D. Hellmann, MD, Daniel R. Gomez, MD, Jamie E. Chaft, MD, Andreas Rimner, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100197- (2021)
Introduction: Durvalumab after concurrent chemoradiation (cCRT) has been found to improve outcomes of patients with unresected stage III NSCLC. However, the survival impact of discontinuing durvalumab early owing to adverse events (AEs) remains unkno
Externí odkaz:
https://doaj.org/article/543a52e006f54f02a1a7c6515b7f698f
Autor:
Zishuo Ian Hu, Matthew D. Hellmann, Jedd D. Wolchok, Monika Vyas, Jinru Shia, Zsofia K. Stadler, Luis A. Diaz, Eileen M. O’Reilly
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-6 (2018)
Abstract Background MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy. Here, we report the first case of acquired resistance to immunotherapy in MMR-D pancreatic cancer. Case presentation A 45-year-old woman with u
Externí odkaz:
https://doaj.org/article/5f26525546d94e53b281a4cb2098caa1
Autor:
Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne J. Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm, Lawrence H. Schwartz, Boris Sepesi, Beow Yong Yeap, Naiyer A. Rizvi, Roy S. Herbst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-15 (2018)
Abstract Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable respon
Externí odkaz:
https://doaj.org/article/650b58462e0a46c6a4a982d979b2522c
Autor:
Donata von Reibnitz, BS, Jamie E. Chaft, MD, Abraham J. Wu, MD, Robert Samstein, MD, PhD, Matthew D. Hellmann, MD, Andrew J. Plodkowski, MD, Zhigang Zhang, PhD, Weiji Shi, MS, Rosalind Dick-Godfrey, BS, Kelly H. Panchoo, BA, Christopher A. Barker, MD, Andreas Rimner, MD
Publikováno v:
Advances in Radiation Oncology, Vol 3, Iss 3, Pp 391-398 (2018)
Purpose: The objective of this study was to evaluate adverse events (AEs) in patients who received both immune checkpoint inhibitors and thoracic radiation therapy (RT). In particular, we compared the rate of toxicities of concurrent versus sequentia
Externí odkaz:
https://doaj.org/article/fc91151be2b946a0b97011bf86638875
Autor:
Akane Inoue-Yamauchi, Paul S. Jeng, Kwanghee Kim, Hui-Chen Chen, Song Han, Yogesh Tengarai Ganesan, Kota Ishizawa, Sylvia Jebiwott, Yiyu Dong, Maria C. Pietanza, Matthew D. Hellmann, Mark G. Kris, James J. Hsieh, Emily H. Cheng
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
Small cell lung cancer cells (SCLC) are differentially sensitive to inhibitors of the BCL-2 family. Here the authors analyse the response to BH3 mimetics in SCLC, delineate patterns of expression of apoptotic proteins correlated with differential sen
Externí odkaz:
https://doaj.org/article/a5d834b769b2400b86f4baf0dda324e5
Autor:
Laurent Dercle, Matthew Fronheiser, Naiyer A. Rizvi, Matthew D. Hellmann, Sabine Maier, Wendy Hayes, Hao Yang, Pingzhen Guo, Tito Fojo, Lawrence H. Schwartz, Binsheng Zhao, David K. Leung
Publikováno v:
Journal of Thoracic Oncology. 18:587-598